{"id":610046,"date":"2022-07-29T18:52:01","date_gmt":"2022-07-29T18:52:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=610046"},"modified":"2022-07-29T18:52:01","modified_gmt":"2022-07-29T18:52:01","slug":"progressive-familial-intrahepatic-cholestasis-market-to-grow-substantially-during-the-forecast-period-delveinsight-key-companies-mirum-pharmaceuticals-vivet-therapeutics-albireo-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/progressive-familial-intrahepatic-cholestasis-market-to-grow-substantially-during-the-forecast-period-delveinsight-key-companies-mirum-pharmaceuticals-vivet-therapeutics-albireo-and-others_610046.html","title":{"rendered":"Progressive Familial Intrahepatic Cholestasis Market to Grow Substantially During the Forecast Period – DelveInsight | Key Companies – Mirum Pharmaceuticals, Vivet Therapeutics, Albireo, and Others"},"content":{"rendered":"
\n
\"Progressive<\/a><\/div>\n
\n
Progressive Familial Intrahepatic Cholestasis Market<\/div>\n<\/div>\n<\/div>\n

DelveInsight’s “Progressive Familial Intrahepatic Cholestasis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Progressive Familial Intrahepatic Cholestasis Market Size and Share in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/em><\/strong><\/p>\n

 <\/p>\n

The Progressive Familial Intrahepatic Cholestasis market<\/a><\/strong> report covers emerging drugs, treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market. <\/p>\n

 <\/p>\n

Progressive Familial Intrahepatic Cholestasis: An Overview<\/strong><\/p>\n

According to the National Institute of Health (NIH), (PFIC) is a disorder that causes progressive liver disease, typically leading to liver failure in which liver cells cannot secrete a digestive fluid called bile. The buildup of bile in liver cells causes liver disease in affected individuals. <\/em><\/p>\n

 <\/p>\n

The average age at onset is three months, although some patients do not develop jaundice until later, even as late as adolescence. <\/em><\/p>\n

 <\/p>\n

Progressive Familial Intrahepatic Cholestasis Market Key Facts<\/strong><\/p>\n

• As per the Progressive Familial Intrahepatic Cholestasis (PFIC) Organization, PFIC affects <\/em><\/p>\n

• The United Kingdom-based study titled “Systematic review of progressive familial intrahepatic cholestasis” conducted by Baker et al. found that the incidence of intrahepatic cholestasis was 1 per 18,000 live births. <\/em><\/p>\n

 <\/p>\n

\"\"<\/p>\n

 <\/p>\n

Find a sample copy of the Progressive Familial Intrahepatic Cholestasis Market report at: Progressive Familial Intrahepatic Cholestasis Market Assessment<\/a><\/strong><\/p>\n

 <\/p>\n

Progressive Familial Intrahepatic Cholestasis Market<\/strong><\/p>\n

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Progressive Familial Intrahepatic Cholestasis market size<\/strong> by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.<\/p>\n

 <\/p>\n

The report gives complete detail of the Progressive Familial Intrahepatic Cholestasis market trend <\/strong>for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.<\/p>\n

 <\/p>\n

Progressive Familial Intrahepatic Cholestasis Epidemiology<\/strong><\/p>\n

The epidemiology section covers detailed insights into the historical and current Progressive Familial Intrahepatic Cholestasis patient pool and forecasted trends for every seven major countries (7MM)  from 2019 to 2032. <\/p>\n

 <\/p>\n

Progressive Familial Intrahepatic Cholestasis Epidemiology Segmentation<\/strong><\/p>\n

• Prevalent Population of PFIC<\/p>\n

• Type-specific Prevalent Population of PFIC <\/p>\n

• Diagnosed and Treatable Cases of PFIC<\/p>\n

 <\/p>\n

Progressive Familial Intrahepatic Cholestasis Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Progressive Familial Intrahepatic Cholestasis market<\/strong> or expected to get launched in the market during the study period. The analysis covers Progressive Familial Intrahepatic Cholestasis market uptake by drugs, patient uptake by therapies, and sales of each drug. <\/p>\n

 <\/p>\n

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.<\/p>\n

 <\/p>\n

The report also covers the Progressive Familial Intrahepatic Cholestasis Pipeline Development Activities<\/strong> and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n

 <\/p>\n

Some of the key companies in the Progressive Familial Intrahepatic Cholestasis Market<\/a> include:<\/strong><\/p>\n

• Mirum Pharmaceuticals<\/p>\n

• Vivet Therapeutics<\/p>\n

• Albireo<\/p>\n

And many others<\/p>\n

 <\/p>\n

Progressive Familial Intrahepatic Cholestasis Therapies covered in the report include:<\/strong><\/p>\n

• Maralixibat (Mirum Pharmaceuticals)<\/p>\n

• VTX-803 (Vivet Therapeutics)<\/p>\n

And many more<\/p>\n

 <\/p>\n

Learn more about the emerging therapies & key companies: Progressive Familial Intrahepatic Cholestasis Therapeutics Market<\/a><\/strong><\/p>\n

 <\/p>\n

Table of Content (TOC)<\/strong><\/p>\n

1. Key Insights<\/p>\n

2. Executive Summary <\/p>\n

3. Progressive Familial Intrahepatic Cholestasis Competitive Intelligence Analysis<\/p>\n

4. Progressive Familial Intrahepatic Cholestasis Market Overview at a Glance<\/p>\n

5. Progressive Familial Intrahepatic Cholestasis Disease Background and Overview<\/p>\n

6. Progressive Familial Intrahepatic Cholestasis Patient Journey<\/p>\n

7. Progressive Familial Intrahepatic Cholestasis Epidemiology and Patient Population<\/p>\n

8. Progressive Familial Intrahepatic Cholestasis Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n

9. Progressive Familial Intrahepatic Cholestasis Unmet Needs<\/p>\n

10. Key Endpoints of Progressive Familial Intrahepatic Cholestasis Treatment<\/p>\n

11. Progressive Familial Intrahepatic Cholestasis Marketed Products<\/p>\n

12. Progressive Familial Intrahepatic Cholestasis Emerging Therapies<\/p>\n

13. Progressive Familial Intrahepatic Cholestasis Seven Major Market Analysis<\/p>\n

14. Attribute Analysis<\/p>\n

15. Progressive Familial Intrahepatic Cholestasis Market Outlook (7 major markets)<\/p>\n

16. Progressive Familial Intrahepatic Cholestasis Access and Reimbursement Overview<\/p>\n

17. KOL Views on the Progressive Familial Intrahepatic Cholestasis Market.<\/p>\n

18. Progressive Familial Intrahepatic Cholestasis Market Drivers<\/p>\n

19. Progressive Familial Intrahepatic Cholestasis Market Barriers<\/p>\n

20. Appendix<\/p>\n

21. DelveInsight Capabilities<\/p>\n

22. Disclaimer<\/p>\n

 <\/p>\n

Get the Detailed TOC of the Progressive Familial Intrahepatic Cholestasis Market report here: Progressive Familial Intrahepatic Cholestasis Report<\/a><\/strong><\/p>\n

 <\/strong><\/p>\n

About DelveInsight<\/strong><\/p>\n

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Ankit Nigam
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +19193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/report-store\/progressive-familial-intrahepatic-cholestasis-pfic-market<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Progressive Familial Intrahepatic Cholestasis Market DelveInsight’s “Progressive Familial Intrahepatic Cholestasis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Progressive Familial Intrahepatic Cholestasis Market Size and … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,404,416],"tags":[],"class_list":["post-610046","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/610046","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=610046"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/610046\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=610046"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=610046"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=610046"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}